Tumour Necrosis Factor alpha (TNFalpha) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFalpha blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFalpha blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFalpha blockers-associated Multiple Sclerosis.

Lucchini, M., Giuffrè, G. M., Nociti, V., Bianco, A., De Fino, C., Losavio, F. A., Presicce, G., Calabresi, P., Mirabella, M., Defining the disease course of TNFα blockers-associated Multiple Sclerosis, <<JOURNAL OF NEUROIMMUNOLOGY>>, 2021; 353 (N/A): 577525-N/A. [doi:10.1016/j.jneuroim.2021.577525] [http://hdl.handle.net/10807/170068]

Defining the disease course of TNFα blockers-associated Multiple Sclerosis

Lucchini, Matteo
;
Giuffrè, Guido Maria;Nociti, Viviana;Bianco, Assunta;De Fino, Chiara;Calabresi, Paolo;Mirabella, Massimiliano
2021

Abstract

Tumour Necrosis Factor alpha (TNFalpha) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFalpha blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFalpha blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFalpha blockers-associated Multiple Sclerosis.
Inglese
Lucchini, M., Giuffrè, G. M., Nociti, V., Bianco, A., De Fino, C., Losavio, F. A., Presicce, G., Calabresi, P., Mirabella, M., Defining the disease course of TNFα blockers-associated Multiple Sclerosis, <<JOURNAL OF NEUROIMMUNOLOGY>>, 2021; 353 (N/A): 577525-N/A. [doi:10.1016/j.jneuroim.2021.577525] [http://hdl.handle.net/10807/170068]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/170068
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact